Making Strides in Targeting PARP, ATR, ATM, WEE1 & POLθ

Select the Optimal Combination Partner, Utilize Biomarkers, & Identify Novel Targets to Overcome DDR Inhibitor Resistance & Improve Patient Stratification to Supercharge the Next Wave of DDR Inhibitors with Lower Toxicities.